TY - GEN
T1 - Anticancer activity of Hypericum mysorense
AU - Chandrashekhar, Raghu H
AU - Vasanth Raj, P.
AU - Rao, Venkata J
AU - Udupa, N.
PY - 2009
Y1 - 2009
N2 - Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml and 31.25 μg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 μg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p<0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p<0.001) increased the life span to 30.33 ± 1.02 (p<0.001) days.
AB - Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml and 31.25 μg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 μg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p<0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p<0.001) increased the life span to 30.33 ± 1.02 (p<0.001) days.
UR - http://www.scopus.com/inward/record.url?scp=77950850807&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950850807&partnerID=8YFLogxK
U2 - 10.1109/ICBPE.2009.5384082
DO - 10.1109/ICBPE.2009.5384082
M3 - Conference contribution
AN - SCOPUS:77950850807
SN - 9781424447640
T3 - 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings
BT - 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings
T2 - 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009
Y2 - 2 December 2009 through 4 December 2009
ER -